Sanofi says CDC panel unanimously recommends use of Beyfortus for infants

The U.S. Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices, or ACIP, voted unanimously 10 to 0 to recommend routine use of Sanofi (SNY) and AstraZeneca’s (AZN) Beyfortus for the prevention of respiratory syncytial virus, or RSV, lower respiratory tract disease for newborns and infants below 8 months of age born during or entering their first RSV season, Sanofi announced. “The Committee also voted unanimously 10 to 0 to recommend routine use of Beyfortus for children aged 8 to 19 months who are at increased risk of severe RSV disease and entering their second RSV season. Additionally, the ACIP voted unanimously 11 to 0 to include Beyfortus in the Vaccines for Children program. Beyfortus will be available in the U.S. ahead of the upcoming 2023-2024 RSV season,” Sanofi said.